Fibrosis and excessive extracellular matrix production are characteristic features of lacrimal gland chronic GVHD (cGVHD). Tranilast (n-[3,4-anthoranilic acid]), used for fibrotic skin disease, inhibits transforming growth factorb-induced matrix production. We conducted a nonrandomized study comparing 8 patients (five men, three women; median age, 47 years) given topical tranilast with 10 patients (three men, seven women; median age, 37 years) receiving therapy with topical artificial tears, sodium hyaluronate and vitamin A for mild ocular cGVHD. The tranilast group instilled topical tranilast and artificial tears q.i.d., beginning the day of dry eye diagnosis. The ocular surface and tear dynamics of each patient were evaluated before hematopoietic stem cell transplant, at the onset of dry eye and after 3 months of treatment. At 3 months, the scores of the Rose Bengal test and Schirmer test with nasal stimulation had significantly improved in the tranilast group compared with that in the control group (Po0.05). Furthermore, although five control patients (50%) developed severe dry eye within the treatment period, only one tranilast-treated patient (12.5%) did; the rest still had mild dry eye (Po0.05). These results suggest the hypothesis that topical tranilast may effectively retard the progression of mild dry eye associated with cGVHD.
Introduction
Fibrosis and excessive extracellular matrix production are the characteristic features of lacrimal gland chronic GVHD (cGVHD).
1,2 Tranilast (n- [3,4- anthoranilic acid]) (Rizaben) (KISSEI Pharmaceutical Co., Ltd, Nagano, Japan) is a safe and useful drug for treating allergic conjunctivitis, allergic rhinitis and atopic dermatitis, and is prepared from constituents of the leaves of the nandina plant. Tranilast has also been used to treat fibrotic skin disease, because it inhibits transforming growth factor-b-induced matrix production. 3 We investigated the efficacy and safety of topical tranilast for early-stage mild dry eye associated with cGVHD.
Materials and methods
We conducted a preliminary and non-randomized study comparing 8 patients (five men, three women; median age, 47 years) given topical tranilast with 10 patients (three men, seven women; median age, 37 years) receiving therapy with topical artificial tears, sodium hyaluronate and vitamin A for mild ocular cGVHD. We assigned patients to the topical tranilast group (tranilast group) and the control group (the non-tranilast group), depending on the patient's consent to use topical tranilast for the treatment of mild dry eye associated with cGVHD. The controls were patients whose ages, baseline tear functions and ocular surface vital staining characteristics were similar to those of the tranilast group at the diagnosis of mild dry eye associated with cGVHD.
The characteristics of patients in this study are shown in Table 1a and b. All patients for HSCT at Keio University Hospital underwent a standardized clinical and ophthalmologic evaluation under the KEIO Bone Marrow Transplant Program for a 3-month follow-up schedule as a part of a prospective survey, evaluating the late effects of HSCT. We evaluated all the patients for ophthalmic evaluation before HSCT and 3, 6, 9, 12, 18, 24, 30, 36 and 42 months after HSCT regularly, and on additional occasions when patients developed ocular symptoms after HSCT. 4 According to the Declaration of Helsinki, informed consents regarding the treatment with tranilast eye drops were obtained from all the patients in this study. The examination procedures were approved by the Institutional Review Board.
We diagnosed either early-stage mild dry eye disease related to cGVHD or the so called 'distinctive feature of cGVHD' according to the NIH consensus conference classification in all patients. 5 The definition of dry eye was defined according to the Dry Eye Workshop (DEWS) report 2007 as follows. 6 Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. 6 The eligibility criteria for treatment with topical tranilast were as follows: (1) shortly after the diagnosis of mild dry eye after HCST; (2) absence of active systemic or ocular infections, or other ocular diseases. The systemic immunosuppressive treatment for GVHD did not change, and nor were any topical immunosuppressants used throughout the study (Table 1a and b). Briefly, posttransplant GVHD prophylaxis was attempted with either CsA and MTX or tacrolimus (FK506) and MTX. CsA or FK506 was discontinued around day 180 post-transplant. Myeloablative conditioning regimen was used for all the recipients in this study.
The baseline tear functions and ocular surface staining were not significantly different between the two groups before topical tranilast treatment ( Table 2) .
Patients were instructed to instill tranilast drops q.i.d. shortly after the diagnosis of dry eye and were evaluated before HSCT, at the onset of dry eye and 3 months after the initiation of topical tranilast treatment in the tranilast group. The baseline treatment protocol of topical artificial tears, vitamin A and/or sodium hyaluronate eye drop in both groups was the same and also did not change during the study. Patients used topical artificial tears, vitamin A and/or sodium hyaluronate five times in each eye per day throughout this study.
Evaluations included assessments of the pre-corneal tear film, and the extent of conjunctival and corneal staining using Rose Bengal, a marker of de-epithelialized areas and of the loss of goblet cells on the ocular surface, and fluorescein, a marker of corneal epithelial cell defects. The strength of the Rose Bengal staining was recorded for the temporal and nasal conjunctiva and the cornea, and was quantified on a scale of 0 to 9. The fluorescein staining, of only the cornea, was rated from 0 to 3. 4, 7 The tear break-up time was measured and three readings were taken. The Schirmer test was performed with nasal stimulation, a marker of maximum reflex tearing and normal lacrimal function, and without nasal stimulation, a marker of basal tearing. Mild dry eye was defined as abnormality of the ocular surface (Rose Bengal scoreX3, fluorescein scoreX1) without reduced reflex tearing (Schirmer test with nasal stimulation410 mm) and/or Grades 1 and 2 of the dry eye severity grading system according to the Dry Eye Work Shop report 2007. Severe dry eye was defined with reduced reflex tearing (Schirmer test with nasal stimulation p10 mm), with ocular surface abnormality (Rose Bengal score X3 and/or fluorescein score X3), and/or Grade 3 and 4 according to the DEWS report. 4, 6, 7 
Results
The mean score of the Schirmer test with nasal stimulation changed from 15.8±12.1 at the onset of dry eye to 22.0 ± 10.1 mm at the 3-month follow-up in the tranilast group and from 13.0±9.6 to 9.9±10.6 mm in the non-tranilast group. These differences were significant at the 3-month follow-up (Po0.05) ( Table 2 and Figure 1 ). The mean Rose Bengal scores in the tranilast group were significantly lower than in the non-tranilast group at the final follow-up (Po0.05) ( Table 2 ). Furthermore, although five patients in the non-tranilast group (50%) developed severe dry eye within three months of dry-eye onset, only one patient (12.5%) did in the tranilast group; the rest still had mild dry eye in the tranilast group (Po0.05). These results indicated that good reflex tearing persisted in the tranilast group at 3 months after the diagnosis of dry eye, in contrast to the non-tranilast group.
The differences between the mean values of tear break-up time, Schirmer test without nasal stimulation and the fluorescein staining did not reach statistical significance by the end point of this study. However, there was a tendency of improvement in fluorescein scores and tear break-up times in the tranilast group after treatment. The value of the fluorescein score (1.8±0.83) and BUT (5.9±2.6) suggested mild dry eye in accordance with the DEWS report Grade 2 at the end point of this study in the tranilast group, whereas the value of the fluorescein score (3.3±2.3) and BUT (4.4±2.7) in the non-tranilast group indicated that the degree of dry eye was more severe in accordance with the DEWS report Grade 3 at the end of this study. Non-stimulated Schirmer test might have been less sensitive to detect benefit, because it is irritating, and therefore evokes reflex tearing causing false-negative results and the change is likely random.
The intensity of dry eye symptom was weak at the time of diagnosis for early stage of mild dry eye at the baseline. The intensity of the worst symptom increased and deteriorated rapidly in half (five cases) of the non-tranilast group (Table  1b) . In contrast, it worsened or deteriorated in none of the patients, improved in two cases and remained unchanged in six cases at 3 months after the initiation of treatment in the tranilast group (Table 1a) . Finally, no serious adverse events were observed in the tranilast and non-tranilast groups.
Discussion
In this preliminary study, we observed significant improvements in reflex tearing and Rose Bengal scores at the end of the study in the tranilast group compared with those in the non-tranilast group. In addition, there is a tendency to improve the tear film break-up times and fluorescein scores at the end of this study in the tranilast group compared with those in the non-tranilast group. None of the patients in the tranilast group showed a deterioration of their symptoms, whereas half of the patients in the non-tranilast group did. These results provide the hypothesis that topical tranilast may effectively retard the progression of mild dry eye associated with cGVHD. One of the limitations in this study was the lack of randomization and the refusal to participate in the treatment assignment group of this study. Another limitation was the small number of patients, which might invite biases. However, observations from the preliminary results of this study introduce interesting Topical tranilast to treat dry eye caused by chronic GVHD Y Ogawa et al Symptom at 3 months after diagnosis: 0, unchanged; 1, improve; 2, progressively worsened.
Topical tranilast to treat dry eye caused by chronic GVHD Y Ogawa et al concepts of preventive intervention and justify further randomized, double blinded and placebo-controlled study in a larger subset of patients. Tranilast (n-[3,4-anthoranilic acid]) inhibits the actions of transforming growth factor-b, a profibrotic growth factor that is pathogenically related to the excessive accumulation of collagenous matrix in a wide range of organs and various diseases. 3, [8] [9] [10] It is used to treat scleroderma and other skin disorders related to excessive fibrosis. 10, 11 Furthermore, tranilast is potentially useful for suppressing the progression of early diabetic nephropathy. 12 Tranilast has several other antifibrotic effects, including some exerted through the suppression of NFkB. 13 These include attenuating the CTGF-induced extracellular matrix accumulation in renal cells, 8 inhibiting the production of PDGF and IL-1 by monocytes and macrophages and inhibiting the production of MCP-1 by rat mesangial cells. 13 Although the lacrimal gland biopsy samples were not available to us to observe histopathological changes in this study, our findings suggest the hypothesis that tranilast may also be effective in retarding the fibrotic changes of lacrimal gland pathology in cGVHD, a characteristic feature of ocular cGVHD.
We recently confirmed that early fibrosis in the lacrimal gland and conjunctiva preferably occurs around mediumsized ducts, including the orifices of the main excretory ducts close to the ocular surface.
2,14 Therefore, it is likely that the topical tranilast might function to prevent the superficial fibrosis around these orifices of ducts near the outermost ocular surface rather than the deep lacrimal gland region, where the intact acini of the lacrimal gland were present at the early stage of mild dry eye.
Previous ex vivo and experimental data, as well as results from former clinical trials [8] [9] [10] [11] [12] [13] and our study provide some evidence for therapeutic efficacy and rationale for further clinical trials. Clearly, more studies in animals to determine whether lacrimal gland fibrosis is inhibited by topical tranilast, and a better designed human study are necessary for further clarification on the role of this agent. Better management of dry eye may even be possible by combining topical immunosuppressants with topical or oral tranilast therapy, which requires further prospective study.
In summary, this preliminary study may provide a hypothesis that topical tranilast could be therapeutically beneficial in the early stage of mild dry eye associated with cGVHD. Our study suggests some aspects, including the use of a new agent for the indication, and introduces the concept of preventive intervention before severe dry eye symptoms develop. It is very difficult to interpret this marginal improvement in a design that is non-blinded, non-randomized and non-placebo-controlled. A clinical trial as a randomized, blinded and placebo-controlled study is currently underway by our group. Safe and specific interventions for inhibiting the fibrotic changes of dry eye associated with cGVHD are clearly needed as soon as possible.
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The authors declare no conflict of interest. stimulation in the tranilast and non-tranilast groups before HSCT, at the onset of dry eye and 3 months after the onset of dry eye. The mean score of the Schirmer test with nasal stimulation, that is, reflex tearing changed from 15.8 ± 12.1 at the onset of dry eye to 22.0 ± 10.1 mm at the 3-month follow-up in the tranilast group and from 13.0±9.6 to 9.9±10.6 mm in the non-tranilast group. These differences were statistically significant at the 3-month follow-up (Po0.05). NS ¼ not significant.
